Sinopharm Group Co ( (HK:1099) ) has provided an update.
Sinopharm Group Co. Ltd. announced the preliminary financial data for its subsidiary, Sinopharm Accord, for the year ended December 31, 2024. The report highlights a decrease in revenue by 1.46% and a significant drop in operating profit by 76.76%, indicating challenges in maintaining profitability. The net profit attributable to shareholders also fell by 59.83%, reflecting a tough financial year for the company. Despite these declines, the equity attributable to shareholders saw a slight increase of 1.46%, suggesting some resilience in shareholder value.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the pharmaceutical industry, focusing on the distribution and retail of pharmaceutical and healthcare products. Its subsidiary, Sinopharm Accord, is listed on the Shenzhen Stock Exchange and plays a significant role in the company’s market presence.
YTD Price Performance: -8.47%
Average Trading Volume: 866
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.82B
See more insights into 1099 stock on TipRanks’ Stock Analysis page.